Value-Based Care

Just a decade ago, physicians were spending an average of 8.7 hours per week on administrative tasks such as maintaining patients’ health records, coordinating referrals, and processing claims. That number has more than tripled today to nearly 28 hours a week in some practices. Read More ›

Metrics to Keep in Mind for Value-Based Cancer Care  Not all metrics are created equal.  Read More ›

At the AVBCC 12th Annual Summit in 2022, a panel of experts from Upstream Partners discussed the current state of value-based agreements (VBAs) in pharma and what lies ahead. Read More ›

Value-based or alternative payment models have yet to deliver the cost-savings in oncology hoped for when these models were proposed, said experts at the 2020 virtual National Comprehensive Cancer Network Oncology Policy Summit during a panel discussion on best practices for value-based agreements. Read More ›

Value-based drug purchasing, better coordination of care delivery, and earlier institution of palliative care were among the measures to lower the cost of cancer care that were suggested during a panel discussion at the 2020 virtual National Comprehensive Cancer Network (NCCN) Oncology Policy Summit. The discussion was moderated by Clifford Goodman, PhD, Senior Vice President, Comparative Effectiveness Research, the Lewin Group. Read More ›

An analysis of the Value Framework of the American Society of Clinical Oncology (ASCO) shows that the Net Health Benefit score of cancer drugs continues to evolve over time after their FDA approval, based on data presented at the ASCO 2020 virtual annual meeting. This analysis showed a substantial change in more than 25% of cancer drugs in their Net Health Benefit 3 years after their initial approval. Read More ›

As the complexity of cancer care continues to evolve, adhering to evidence-based treatment guidelines is a growing challenge for oncologists. Read More ›

Cemiplimab-rwlc (Libtayo), a new PD-1 inhibitor, has transformed the treatment of advanced cutaneous squamous-cell carcinoma (CSCC), significantly extending survival for patients. Read More ›

New research highlights the importance of germline analysis in the identification of germline alterations for cancer treatment. According to a large analysis presented at the ASCO 2020 virtual annual meeting, nearly 9% of patients with advanced cancer harbor a targetable germline variant. Read More ›